GenapSys, a Redwood City, CA-based company developing a scalable electronic sequencing platform, raised $70m in Series D equity financing.
Backers included Farallon Capital Management, L.L.C., Soleus Capital, an affiliate of PBM Capital, and additional new investors. In conjunction with the funding, Bob Zollars and a representative of Farallon Capital have been appointed to GenapSys’ Board of Directors.
The company intends to use the funds to continue advancing its semiconductor based next-generation sequencing (NGS) platform.
Led by Jason Myers, Ph.D., Chief Executive Officer, and Founder and Chairman Dr. Hesaam Esfandyarpour, GenapSys is a company focused on the advancement of universal access to genomic information by delivering a genomic sequencing ecosystem that empowers both academic and clinical research applications. Its system leverages a proprietary electrical microfluidic sequencing chip with a scalable number of detectors, allowing for a wide range of applications. GenapSys products are provided for Research Use Only. Not for use in diagnostic procedures.
Bob Zollars brings over 35 years of leadership experience in healthcare technology and services with a proven track record of growth and value creation. Mr. Zollars is a senior advisor at Frazier Healthcare Partners, in their growth equity business. Previously, he was group president at Cardinal Health and was responsible for five of their subsidiary companies, Zollars also led four different operating divisions at Baxter Healthcare. He was chairman and CEO of Vocera Communications, Inc. and was previously chairman and CEO of Neoforma, where he led both companies through successful IPO’s. He serves on the boards of Change Healthcare, Five 9, Kate Farms, and Parata Systems. Mr. Zollars received his M.B.A. in Finance from John F. Kennedy University and graduated magna cum laude with a B.S. in Marketing from Arizona State University where he is now Chair of the Trustees.